# EDGAR Filing Document

**Accession Number:** 0001357459
**File Stem:** 0001493152-25-015874
**Filing Date:** 2025-9
**Character Count:** 4216
**Document Hash:** c5d5733606ee81402456b1bcc32807b0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-015874.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001493152-25-015874

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250929

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PALISADE BIO, INC.
- **CENTRAL INDEX KEY:** 0001357459
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 522007292
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 7750 EL CAMINO REAL, SUITE 5200
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92009
- **BUSINESS PHONE:** (858) 704-4900

**MAIL ADDRESS:**
- **STREET 1:** 7750 EL CAMINO REAL, SUITE 5200
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Seneca Biopharma, Inc.
- **DATE OF NAME CHANGE:** 20200127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neuralstem, Inc.
- **DATE OF NAME CHANGE:** 20060324

---

| | |
|:---|:---|
| ![](formcorresp_001.jpg) | ![](formcorresp_002.jpg) |

---

September 29, 2025

***VIA EDGAR***

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Doris Stacey Gama <br> Alan Campbell

---

| | |
|:---|:---|
| **Re:** | **Palisade Bio, Inc.** |
|  | **Draft Registration Statement on Form S-1** |
|  | **Submitted July 3, 2025** |
|  | **CIK No. 0001357459** |

---

Ladies and Gentlemen:

On behalf of Palisade Bio, Inc. (the "**Company**"), and in connection with the filing via EDGAR of its Registration Statement on Form S-1 (the "***Registration Statement***"), this letter responds to the comment set forth in the letter to the Company dated July 14, 2025 from the staff of the Securities and Exchange Commission (the "***Staff***").

For your convenience, we have repeated and numbered the Staff's comment from the July 14, 2025 letter in italicized print, and the Company's response is provided below the comment.

**<u>General</u>**

***1.***  ***We note you are offering units with each unit consisting of one share of common stock, one Series 1 warrant and one Series 2 warrant, and that the Series 1 warrants will be exercisable until the earlier of (i) the one year anniversary of the Initial Exercise Date and (ii) within 30 days of reporting positive clinical data from a cohort of fibrostenotic Crohn's ("FSCD") patients in your ongoing Phase 1 study. You also state on page 4 that you have already reported positive results from three cohorts (SAD, MAD, FE) of your Phase 1 study on May 27, 2025 and that you plan to initiate an additional exploratory Phase 1b cohort. With respect to the Series 1 warrants, please state which cohort(s) trigger the exercise provision, define the "positive" clinical data required and discuss whether this exercise provision could be triggered prior to the company obtaining shareholder approval for the issuance of the shares underlying the warrants.*** 

In response to the Staff's comment, the Company respectfully advises the Staff that because of the new offering structure set forth in the Registration Statement, and more specifically because the Company is no longer offering units nor is the Company offering any Series 1 warrants or other securities consisting of any Series 1 warrants, the Company does not believe that this comment is still applicable.

*[Remainder of page intentionally left blank.]*

\* \* \* \* \*

Securities and Exchange Commission<br>September 29, 2025<br>Page 2<br>

Please do not hesitate to contact me at (858) 436-8064 if you have any questions or would like additional information regarding this matter.

Very truly yours,

---

| | |
|:---|:---|
| GUNDERSON DETTMER STOUGH | GUNDERSON DETTMER STOUGH |
| VILLENEUVE FRANKLIN & HACHIGIAN, LLP | VILLENEUVE FRANKLIN & HACHIGIAN, LLP |
| */s/ Jeffrey C. Thacker* | */s/ Jeffrey C. Thacker* |
| cc: | JD Finley |
|  | **Palisade Bio, Inc.** |
|  | Ryan J. Gunderson |
|  | **Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP** |

---